XM 412 | CAS#177932-89-7 | inhibitor

MedKoo Cat#: 584773 | Name: XM 412

Description:

WARNING: This product is for research use only, not for human or veterinary use.

XM 412, also known as DMP 450, is an HIV protease inhibitor.

Chemical Structure

XM 412

CAS#177932-89-7 (dimesylate)

Theoretical Analysis

MedKoo Cat#: 584773

Name: XM 412

CAS#: 177932-89-7 (dimesylate)

Chemical Formula: C35H44N4O9S2

Exact Mass: 728.2550

Molecular Weight: 728.88

Elemental Analysis: C, 57.68; H, 6.08; N, 7.69; O, 19.76; S, 8.80

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

174391-92-5 (free base) 177932-89-7 (dimesylate)

Synonym

XM 412; DMP 450; Mozenavir dimesylate; Mozenavir dimesilate

IUPAC/Chemical Name

2H-1,3-Diazepin-2-one, 1,3-bis((3-aminophenyl)methyl)hexahydro-5,6-dihydroxy-4,7-bis(phenylmethyl)-, (4R,5S,6S,7R)-, dimethanesulfonate (salt)

InChi Key

HINZVVDZPLARRP-YSVIXOAZSA-N

InChi Code

InChI=1S/C33H36N4O3.2CH4O3S/c34-27-15-7-13-25(17-27)21-36-29(19-23-9-3-1-4-10-23)31(38)32(39)30(20-24-11-5-2-6-12-24)37(33(36)40)22-26-14-8-16-28(35)18-26;2*1-5(2,3)4/h1-18,29-32,38-39H,19-22,34-35H2;2*1H3,(H,2,3,4)/t29-,30-,31+,32+;;/m1../s1

SMILES Code

O=C1N(CC2=CC=CC(N)=C2)[C@H](CC3=CC=CC=C3)[C@H](O)[C@@H](O)[C@@H](CC4=CC=CC=C4)N1CC5=CC=CC(N)=C5.CS(=O)(O)=O.CS(=O)(O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 728.88 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Hodge CN, Aldrich PE, Bacheler LT, Chang CH, Eyermann CJ, Garber S, Grubb M, Jackson DA, Jadhav PK, Korant B, Lam PY, Maurin MB, Meek JL, Otto MJ, Rayner MM, Reid C, Sharpe TR, Shum L, Winslow DL, Erickson-Viitanen S. Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450. Chem Biol. 1996 Apr;3(4):301-14. PubMed PMID: 8807858. 2: Hylton KG, Main AD, McElwee-White L. Catalytic carbonylation of functionalized diamines: application to the core structure of DMP 323 and DMP 450. J Org Chem. 2003 Feb 21;68(4):1615-7. PubMed PMID: 12585919. 3: Grubb MF, Robinson CA, White SJ, Krauthauser CL, Shum L. Determination of a HIV protease inhibitor (DMP 450) in animal and human plasma by solid-phase extraction and high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1996 Apr 12;678(2):303-8. PubMed PMID: 8738035. 4: Ala PJ, Huston EE, Klabe RM, McCabe DD, Duke JL, Rizzo CJ, Korant BD, DeLoskey RJ, Lam PY, Hodge CN, Chang CH. Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors. Biochemistry. 1997 Feb 18;36(7):1573-80. Erratum in: Biochemistry 1997 May 27;36(21):6556. PubMed PMID: 9048541. 5: Vickery RD, Maurin MB. Utility of microcalorimetry in the characterization of the browning reaction. J Pharm Biomed Anal. 1999 Jun;20(1-2):385-8. PubMed PMID: 10704046. 6: De Lucca GV, Jadhav PK, Waltermire RE, Aungst BJ, Erickson-Viitanen S, Lam PY. De novo design and discovery of cyclic HIV protease inhibitors capable of displacing the active-site structural water molecule. Pharm Biotechnol. 1998;11:257-84. Review. PubMed PMID: 9760684. 7: Nugiel DA, Jacobs K, Kaltenbach RF, Worley T, Patel M, Meyer DT, Jadhav PK, De Lucca GV, Smyser TE, Klabe RM, Bacheler LT, Rayner MM, Seitz SP. Preparation and structure-activity relationship of novel P1/P1'-substituted cyclic urea-based human immunodeficiency virus type-1 protease inhibitors. J Med Chem. 1996 May 24;39(11):2156-69. PubMed PMID: 8667359. 8: Patel M, Bacheler LT, Rayner MM, Cordova BC, Klabe RM, Erickson-Viitanen S, Seitz SP. The synthesis and evaluation of cyclic ureas as HIV protease inhibitors: modifications of the P1/P1' residues. Bioorg Med Chem Lett. 1998 Apr 7;8(7):823-8. PubMed PMID: 9871548. 9: Aungst BJ, Nguyen NH, Bulgarelli JP, Oates-Lenz K. The influence of donor and reservoir additives on Caco-2 permeability and secretory transport of HIV protease inhibitors and other lipophilic compounds. Pharm Res. 2000 Oct;17(10):1175-80. PubMed PMID: 11145221. 10: Rayner MM, Cordova B, Jackson DA. Population dynamics studies of wild-type and drug-resistant mutant HIV in mixed infections. Virology. 1997 Sep 15;236(1):85-94. PubMed PMID: 9299620. 11: Ala PJ, DeLoskey RJ, Huston EE, Jadhav PK, Lam PY, Eyermann CJ, Hodge CN, Schadt MC, Lewandowski FA, Weber PC, McCabe DD, Duke JL, Chang CH. Molecular recognition of cyclic urea HIV-1 protease inhibitors. J Biol Chem. 1998 May 15;273(20):12325-31. PubMed PMID: 9575185. 12: Vilar S, Villaverde MC, Sussman F. Inhibitor docking screened by the modified SAFE_p scoring function: application to cyclic urea HIV-1 PR inhibitors. J Comput Chem. 2007 Oct;28(13):2216-25. PubMed PMID: 17450567. 13: De Lucca GV, Kim UT, Liang J, Cordova B, Klabe RM, Garber S, Bacheler LT, Lam GN, Wright MR, Logue KA, Erickson-Viitanen S, Ko SS, Trainor GL. Nonsymmetric P2/P2' cyclic urea HIV protease inhibitors. Structure-activity relationship, bioavailability, and resistance profile of monoindazole-substituted P2 analogues. J Med Chem. 1998 Jun 18;41(13):2411-23. PubMed PMID: 9632373.